HCV Research

We have an effective vaccine for HBV in order to treat HBV patients to defeat their disease, but unfortunately, there is none against the HCV virus, despite the existence of far many more HCV patients worldwide.

Chronic HCV infection can provoke liver inflammation, bringing about degenerative organ damage, resulting in cirrhosis and hepatocellular carcinoma (liver cancer). After a first stage, chronic HCV infection appears in a rate of 75- 85 per cent of the cases. Often it leads to liver failure and subsequent liver transplantation.

Like with chronic HBV infection, in its early phase, chronic HCV infection is easily underestimated, as it does not show particular symptoms and can hardly be detected. This means that, without knowing, many persons have already been infected.

Advantages of DDX3i Therapy

Targeting a cellular host factor instead of a viral protein, the threshold of resistance development to DDX3i therapy will be very high. This is however just one of the advantages of host factor based approaches.

HCV has many genotypes; each of which has its unique genetic characteristics and subsequent response to available antiviral agents. Targeting a host factor on the other hand bypasses these acquired resistances, because each viral genotype in the end still makes equal use of the host cells biological apparatus.

As such, DDX3i therapy has proven equally effective against a wide array of HCV genotypes, instead of creating a different response in each viral subtype, such as currently is the case with viral protein based therapies.

Co-infection of HCV and HIV occurs frequently and as such requires combination treatments of ART drugs and HCV combination therapies. Even in the best of scenarios where modern HAART drugs are combined with the latest generations of non-structural viral protein NS5 based treatments, the side effects are still considerable.

Especially when peg interferon is also subscribed, the co-infection treatment possibilities are severely compromised. DDX3i based treatment on the other hand, has none of these shortcomings.

Instead, both HIV and HCV viruses respond equally well to DDX3 host factor inhibition, and as such this extremely difficult subgroup of co-infected HIV / HCV patients is likely to benefit considerably from DDX3i therapy.